{"entity":{"id":"nct07377526","kind":"trial","name":"TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer","aka":[],"tldr":"This study tests TROP-2-directed treatment; the registry reports that it is suspended.","summary":"The registry lists NCT07377526 as suspended, last updated 2026-07-31. Enrolment is 37 planned participants, an estimate. Interventions: TGFBR2 KO CAR27/IL-15 NK cells. Primary measures include Safety and Adverse Events (AEs). The registry reason for stopping is: PI Request No results are posted in the registry; this does not exclude separate publications. The title and brief summary specify intraperitoneal cells with oral belzutifan, but the intervention table incorrectly describes the cells as given by mouth; the route is not reproduced as a dosing recommendation.","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07377526","url":"https://clinicaltrials.gov/study/NCT07377526"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07377526","phase":"1/2","setting":"Phase 1/2 Study Of IL15-Transduced, TGFBR2 KO, TROP2 CAR- Engineered Cord Blood-Derived NK Cells Administered Intraperitoneally And Intravenously In Combination With Oral Belzutifan For The Management Of Pancreatic Cancer","sponsor":"M.D. Anderson Cancer Center","started":"2026-05-26","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07377526/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}]}}